Back to results

Phase II Study of Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

Protocol #

HCRN-BRE20-468

Trial Phase:

Phase II

Principal Investigator:

Ross, Masey

Cancer Type
  • Breast
Study Site
  • Virginia Commonwealth University

Male or female age>/=18 years at the time of consent.
NOTE: Both pre- and post-menopausal women are eligible
Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer based on the most recently
analyzed tissue sample and all tested by local laboratory.
Patient has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or
SISH) test is required by local laboratory testing and based on the most recently analyzed tissue sample.
Patients have had adequate local treatment for locoregional recurrence (LRR) of breast cancer

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Treatment
  • Research Study Team Lindsey Gwaltney, MS, RN
    Phone: +1 804-628-2112
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: